UCB has announced the successful completion of its first fully automated lead discovery experiment, achieved in collaboration with Cyclofluidic and its technology platform.

The Cyclofluidic Integrated Discovery Platform (CIDP) has been produced to design, make and screen potential drug molecules against selected targets, significantly accelerating the new drug discovery process.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The successful completion was achieved with a target called Thrombin, a molecule associated with strokes, just over three years since Cyclofluidic’s founding in 2008.

The technology platform is designed to allow researchers to test potential new medicines in a shorter time and at cheaper expense in comparison to the 10-15 years and up to £1bn it can currently take to develop a new medication.

The CIDP uses microfluidic technology, online biochemical assays and automated drug design algorithms to create and screen potential drug molecules, reducing the learning cycle phase of drug development and integrating the processes, allowing molecules to be assayed in minutes rather than weeks.

See Also:

The UK Government’s Technology Strategy Board has co-funded Cyclofluidic’s research and development, whilst also facilitating an innovative partnership between UCB and Pfizer relating to lead molecule discovery.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

UCB Chemistry vice president, Dr Warrelow, said: "To have achieved this within three years is extremely exciting and offers the promise of further ground-breaking science that could significantly impact small molecule drug discovery in the years ahead."